Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing ...

Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...

Semaglutide, the active ingredient in the anti-obesity drug Wegovy, offers cardiovascular benefits for patients without diabetes who have established heart disease, but price reductions would be ...

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding.

Goodpath, the virtual integrative care provider for chronic conditions, today announced direct-to-employer (DTE) and self-pay access to Wegovy (R) , including both injectable and newly-approved oral ...

Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabs ...

Weight loss drugs are more popular than ever, even in cycling, but do the health benefits some are seeing outweigh the risks ...

Mounjaro is a self-administered injection which received regulatory approval for the treatment of type 2 diabetes and chronic ...